This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Discovery Labs Announces Recent AFECTAIR® Publications

Safety Assessment of a Novel Neonatal Ventilator Circuit Patient Interface Connector for the Delivery of Aerosolized Medication to Mechanically Ventilated Infants Respiratory Therapy.   February- March 2013, Vol. 8, No. 1, Pages 29-33



As part of a safety assessment of AFECTAIR, studies were conducted to determine the dead space volume (volume of gas that remains in device, undelivered to the patient), the resistance to gas flows through AFECTAIR relative to a standard configuration, as well as the interaction between the ventilator circuit gas and the aerosol carrier gas using the two configurations.  Authors concluded that, when used correctly, AFECTAIR has a comparable safety profile to standard wye connectors and aerosol delivery configurations.  Authors also stated that further studies are needed to determine the impact of AFECTAIR on the delivery of aerosolized medications to mechanically ventilated infants.

Use of AFECTAIR may result in an increase in the delivery of aerosolized medication to patients receiving mechanical ventilation.  When delivering aerosolized medication through AFECTAIR to patients receiving mechanical ventilation, a qualified healthcare personnel should closely monitor the response to the aerosolized medication.

About Journal of Aerosol Medicine and Pulmonary Drug Delivery

The Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only authoritative journal delivering innovative articles on the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized drugs in the intubated patient.

About Respiratory Therapy

Respiratory Therapy, the Journal of Pulmonary Technique, brings a new concept in presenting information to respiratory therapy managers and supervisors, respiratory therapists, nurses, researchers and students with the goal of presenting a wide variety of papers in a clear, effective and familiar clinical format.   Respiratory Therapy's international clinical focus ensures readers receive, with every issue, the latest and best information about all aspects of respiratory therapy as actively practiced in a wide variety of clinical venues and modalities.

About Discovery Labs

Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to advance a new standard in respiratory critical care.  Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized, and aerosolized dosage forms. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.  For more information, please visit our website at www.Discoverylabs.com.



2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,671.87 -208.49 -1.24%
S&P 500 1,941.27 -28.80 -1.46%
NASDAQ 4,382.4410 -80.4610 -1.80%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs